Literature DB >> 23969054

Genome Sequence of Salmonella enterica Serovar Typhi Oral Vaccine Strain Ty21a.

Deqi Xu1, John O Cisar, Frédéric Poly, Jinghua Yang, Jason Albanese, Madushini Dharmasena, Tint Wai, Patricia Guerry, Dennis J Kopecko.   

Abstract

Attenuated Salmonella enterica serovar Typhi strain Ty21a is an important vaccine for controlling typhoid fever and serves as an oral vector for delivering heterologous antigens. The key attenuating features of this randomly mutated strain remain in question. Genome sequencing has revealed 679 single nucleotide polymorphisms (SNPs), and will help define alterations contributing to Ty21a safety and immunogenicity.

Entities:  

Year:  2013        PMID: 23969054      PMCID: PMC3751609          DOI: 10.1128/genomeA.00650-13

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Prior genomic sequencing of Salmonella enterica serovar Typhi (1–3) has both stimulated research and increased our understanding of typhoid pathogenesis. Nevertheless, typhoid fever remains a major cause of worldwide morbidity and mortality, with an estimated global annual incidence of 22 million cases and >600,000 deaths (4, 5). The observed increasing antibiotic resistance of typhoid isolates in nature leaves typhoid vaccination as a critically important control measure. Development of the live, attenuated Salmonella enterica serovar Typhi strain Ty21a (6) validated the concept that orally delivered, attenuated enteric bacteria can mimic natural infection in stimulating both mucosal and systemic immune responses without causing disease symptoms (7). Ty21a has been shown to be highly safe (i.e., no reversion to virulence) following administration to >200 million recipients over >25 years. Ty21a, tested in several large clinical trials totaling >500,000 adults and children, has demonstrated overall typhoid protective efficacies of 67 to 96%, which were maintained at high levels through at least 7 full years (8). Importantly, Ty21a attenuation resulted in an enviable balance of reduced virulence and enhanced immunogenicity relative to immunity derived following natural typhoid infections (i.e., only 30 to 35% protection following acute typhoid disease). Ty21a has also been employed as an oral delivery system to protect against other disease agents, such as shigellosis (9–11) and the biodefense threat anthrax (12). Derived from parent strain Ty2, Ty21a was primarily mutated to galE negativity and Vi-capsule nonexpression by random mutagenic methods (6) but was also selected for downregulation of other genes in galactose metabolism (13, 14). Additionally, other mutations (e.g., in rpoS and ilvD) are also known to exist in Ty21a (14). A full accounting of Ty21a genomic mutations has, to date, been lacking. Thus, the intent of these studies has been to enumerate, locate, and analyze all mutations in Ty21a relative to the Ty2 parent. The resulting data are being used to gain a better understanding of Ty21a attenuation (i.e., safety) and enhanced immunogenicity over wild-type strains, information that might be helpful in the development of new attenuated bacterial vaccines. DNA was prepared with a genomic isolation kit (Promega) from L-broth-grown Ty21a obtained from commercially available Vivotif capsules (Crucell/Berna Biotech, Ltd., Switzerland). Initially, a 98% complete Ty21a genomic sequence was derived using a NimbleGen chip-based (high-density microarray) resequencing analysis compared to the published Ty2 genome (NCBI accession number AE014613); this approach resulted in numerous uncalled nucleotides. Separately, a Ty21a genomic sequence obtained from 4× coverage by random 454-based sequencing was determined. These two sequences were used integratively to verify identical genomic regions and to detect areas of disparity. All incongruous regions were resequenced using double-strand sequence analysis for clarification. The Ty21a genome comprises a single circular contig consisting of 4,791,958 bp, with an average G+C content of 52.06%. A total of 4,339 coding regions (open reading frames [ORFs]) were defined in Ty21a using GeneMark (http://opal.biology.gatech.edu/GeneMark) and compared with known Ty2 ORFs by BLAST analysis. A total of 679 SNPs was identified in Ty21a, relative to the published Ty2 genome (2). A detailed analysis of these mutations will be included in future publications.

Nucleotide sequence accession number.

The Salmonella ennterica serovar Typhi strain Ty21a genome sequence has been deposited in GenBank under the accession number CP002099.
  12 in total

1.  The global burden of typhoid fever.

Authors:  John A Crump; Stephen P Luby; Eric D Mintz
Journal:  Bull World Health Organ       Date:  2004-05       Impact factor: 9.408

Review 2.  The mucosal immune system: from fundamental concepts to vaccine development.

Authors:  J R McGhee; J Mestecky; M T Dertzbaugh; J H Eldridge; M Hirasawa; H Kiyono
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

3.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

4.  Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.

Authors:  Manuel Osorio; Yanping Wu; Sunil Singh; Tod J Merkel; Siba Bhattacharyya; Milan S Blake; Dennis J Kopecko
Journal:  Infect Immun       Date:  2009-01-29       Impact factor: 3.441

5.  Comparative genomics of Salmonella enterica serovar Typhi strains Ty2 and CT18.

Authors:  Wen Deng; Shian-Ren Liou; Guy Plunkett; George F Mayhew; Debra J Rose; Valerie Burland; Voula Kodoyianni; David C Schwartz; Frederick R Blattner
Journal:  J Bacteriol       Date:  2003-04       Impact factor: 3.490

Review 6.  Global trends in typhoid and paratyphoid Fever.

Authors:  John A Crump; Eric D Mintz
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

7.  High-throughput sequencing provides insights into genome variation and evolution in Salmonella Typhi.

Authors:  Kathryn E Holt; Julian Parkhill; Camila J Mazzoni; Philippe Roumagnac; François-Xavier Weill; Ian Goodhead; Richard Rance; Stephen Baker; Duncan J Maskell; John Wain; Christiane Dolecek; Mark Achtman; Gordon Dougan
Journal:  Nat Genet       Date:  2008-07-27       Impact factor: 38.330

8.  Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a.

Authors:  Madushini N Dharmasena; Brock W Hanisch; Tint T Wai; Dennis J Kopecko
Journal:  Int J Med Microbiol       Date:  2013-03-07       Impact factor: 3.473

9.  Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector.

Authors:  De-Qi Xu; John O Cisar; Nicholas Ambulos; Donald H Burr; Dennis J Kopecko
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

10.  Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years.

Authors:  Dennis J Kopecko; Heike Sieber; Jose A Ures; Andreas Fürer; Jacqueline Schlup; Ulrich Knof; Andre Collioud; Deqi Xu; Kevin Colburn; Guido Dietrich
Journal:  Int J Med Microbiol       Date:  2009-01-01       Impact factor: 3.473

View more
  5 in total

Review 1.  Novel antigens for enterotoxigenic Escherichia coli vaccines.

Authors:  James Fleckenstein; Alaullah Sheikh; Firdausi Qadri
Journal:  Expert Rev Vaccines       Date:  2014-04-04       Impact factor: 5.217

2.  Identification of Five Novel Salmonella Typhi-Specific Genes as Markers for Diagnosis of Typhoid Fever Using Single-Gene Target PCR Assays.

Authors:  Yuan Xin Goay; Kai Ling Chin; Clarissa Ling Ling Tan; Chiann Ying Yeoh; Ja'afar Nuhu Ja'afar; Abdul Rahman Zaidah; Suresh Venkata Chinni; Kia Kien Phua
Journal:  Biomed Res Int       Date:  2016-11-15       Impact factor: 3.411

Review 3.  Non-Canonical Host Intracellular Niche Links to New Antimicrobial Resistance Mechanism.

Authors:  Michaela Kember; Shannen Grandy; Renee Raudonis; Zhenyu Cheng
Journal:  Pathogens       Date:  2022-02-08

4.  Development of an Acid-Resistant Salmonella Typhi Ty21a Attenuated Vector For Improved Oral Vaccine Delivery.

Authors:  Madushini N Dharmasena; Catherine M Feuille; Carly Elizabeth C Starke; Arvind A Bhagwat; Scott Stibitz; Dennis J Kopecko
Journal:  PLoS One       Date:  2016-09-27       Impact factor: 3.240

Review 5.  Why Is Eradicating Typhoid Fever So Challenging: Implications for Vaccine and Therapeutic Design.

Authors:  Yi-An Yang; Alexander Chong; Jeongmin Song
Journal:  Vaccines (Basel)       Date:  2018-07-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.